ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
Initiative
ESG Report
IR
Stock Index
Official Notice
PR
Press
Library
CAREERS
Recruiting
ENG
Korean
English
home
Title + Content
Title+Content
Title
Content
Search
Number
Title
Author
Date
10
Apatinib, designated as European orphan drug..'Speeding' licensing-out to market
admin
9
HLB submitted Korea & Japan, protocol plan for Apatinib clinical trial phase III
admin
8
HLB speeding up to a Bio Group companies..expects the value of the Life Liver up.
admin
7
Promethera Executes on Asian Expansion Strategy by Attracting Leading Institutional and Strategic Investors from Japan and kore
admin
6
Promethera boosts Series C to €26M to join NASH race
admin
5
Public Institutions like Korea South-East Power Co. help NET & NEP certified companies
admin
4
Nature Review, recognized Apatinib’s potential as 3rd therapeutic agent for gastric cancer
admin
3
HLB obtained NET(New Excellent Technology) certificate on its Fiber Glass Pipe
admin
2
HLB’s Chairman Yangon Jin declares “will put every effort into bio biz to jump to a global firm”
admin
1
Sungchul Lee, CEO of LSKB, will export Targeted anti-cancer therapies to multinational company
admin
<<
<
11
12
13
14
15